These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17371973)

  • 1. Delivery of antigen to CD40 induces protective immune responses against tumors.
    Schjetne KW; Fredriksen AB; Bogen B
    J Immunol; 2007 Apr; 178(7):4169-76. PubMed ID: 17371973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses.
    Rasmussen IB; Oynebråten I; Høydahl LS; Flobakk M; Lunde E; Michaelsen TE; Bogen B; Sandlie I
    Protein Eng Des Sel; 2012 Mar; 25(3):89-96. PubMed ID: 22233931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB; Sandlie I; Bogen B
    Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40 engagement enhances antigen-presenting langerhans cell priming of IFN-gamma-producing CD4+ and CD8+ T cells independently of IL-12.
    Gorbachev AV; Fairchild RL
    J Immunol; 2004 Aug; 173(4):2443-52. PubMed ID: 15294958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40-induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation.
    Clatza A; Bonifaz LC; Vignali DA; Moreno J
    J Immunol; 2003 Dec; 171(12):6478-87. PubMed ID: 14662847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies.
    Lunde E; Western KH; Rasmussen IB; Sandlie I; Bogen B
    J Immunol; 2002 Mar; 168(5):2154-62. PubMed ID: 11859101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
    Ge Y; Xi H; Zhang XG
    Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
    Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
    J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
    Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
    Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting interferon-alpha to dendritic cells enhances a CD8
    Graham JP; Authie P; Karolina Palucka A; Zurawski G
    Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
    Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
    Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.
    Yin W; Gorvel L; Zurawski S; Li D; Ni L; Duluc D; Upchurch K; Kim J; Gu C; Ouedraogo R; Wang Z; Xue Y; Joo H; Gorvel JP; Zurawski G; Oh S
    EBioMedicine; 2016 Mar; 5():46-58. PubMed ID: 27077111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.